PMID- 11270801
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20220309
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
VI  - 39
IP  - 2
DP  - 2001 Feb
TI  - Levels of sICAM-1, sVCAM-1 and MCP-1 in patients with hyperlipoproteinemia IIa 
      and -IIb.
PG  - 48-52
AB  - OBJECTIVE: Hyperlipoproteinemia is one of the factors that are involved in the 
      development of atherosclerosis. One of the mechanisms through which these high 
      plasma lipid levels trigger the formation of atherosclerotic lesions is a change 
      in the expression of adhesion molecules on endothelial and smooth muscle cells. 
      The aim of this study was to evaluate the plasma levels of soluble intracellular 
      adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 
      (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) in patients with Type 
      IIa (HLP-IIa) and IIb (HLP-IIb) hyperlipoproteinemias. SUBJECTS: Twenty patients 
      with HLP-IIa, 20 patients with HLP-IIb and 23 control subjects were studied. To 
      accurately evaluate adhesion molecule levels, we excluded those hyperlipemic 
      patients and control subjects who had an inflammatory disease. METHODS: Plasma 
      sICAM-1, sVCAM-1 and MCP-1 levels were measured by the ELISA method. RESULTS: 
      sVCAM-1 levels in HLP-IIa and HLP-IIb patients (535 +/- 27 ng/ml and 545 +/- 22 
      ng/ml, respectively) did not differ significantly from those in the control group 
      (558 +/- 20 ng/ml). sICAM-1 levels were significantly higher in patients with 
      HLP-IIa and HLP-IIb (279 +/- 10 ng/ml and 322 +/- 12 ng/ml, respectively) 
      compared to the control group (226 +/- 10 ng/ml). MCP-1 levels were significantly 
      higher in HLP-IIa and HLP-IIb patients (151 +/- 12 pg/ml vs 154 +/- 12 pg/ml, 
      respectively) compared to healthy controls (98 +/- 4 pg/ml). sICAM-1 levels in 
      the HLP-IIb group were significantly higher than in the HLP-IIa group. 
      CONCLUSION: The results of the study suggest that lipid abnormalities affect the 
      levels of adhesion molecules and chemokines in plasma.
FAU - Kowalski, J
AU  - Kowalski J
AD  - Department of Clinical Pharmacology, Medical University of Silesia, Katowice, 
      Poland.
FAU - Okopien, B
AU  - Okopien B
FAU - Madej, A
AU  - Madej A
FAU - Makowiecka, K
AU  - Makowiecka K
FAU - Zielinski, M
AU  - Zielinski M
FAU - Kalina, Z
AU  - Kalina Z
FAU - Herman, Z S
AU  - Herman ZS
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
RN  - 0 (Apolipoproteins B)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Triglycerides)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apolipoproteins B/blood
MH  - Chemokine CCL2/*blood
MH  - Cholesterol/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Hyperlipoproteinemia Type II/*blood
MH  - Intercellular Adhesion Molecule-1/*blood
MH  - Male
MH  - Middle Aged
MH  - Triglycerides/blood
MH  - Vascular Cell Adhesion Molecule-1/*blood
EDAT- 2001/03/29 10:00
MHDA- 2001/07/13 10:01
CRDT- 2001/03/29 10:00
PHST- 2001/03/29 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/03/29 10:00 [entrez]
AID - 10.5414/cpp39048 [doi]
PST - ppublish
SO  - Int J Clin Pharmacol Ther. 2001 Feb;39(2):48-52. doi: 10.5414/cpp39048.